Order Article Reprints

Mayayo-Peralta I, Faggion B, Hoekman L, Morris B, Lieftink C, Goldsbrough I, Buluwela L, Siefert JC, Post H, Altelaar M, et al. Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. Cancers. 2021; 13(24):6314. https://doi.org/10.3390/cancers13246314

Mayayo-Peralta, Isabel, Beatrice Faggion, Liesbeth Hoekman, Ben Morris, Cor Lieftink, Isabella Goldsbrough, Lakjaya Buluwela, Joseph C. Siefert, Harm Post, Maarten Altelaar, and et al. 2021. "Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer" Cancers 13, no. 24: 6314. https://doi.org/10.3390/cancers13246314

Mayayo-Peralta, I., Faggion, B., Hoekman, L., Morris, B., Lieftink, C., Goldsbrough, I., Buluwela, L., Siefert, J. C., Post, H., Altelaar, M., Beijersbergen, R., Ali, S., Zwart, W., & Prekovic, S. (2021). Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. Cancers, 13(24), 6314. https://doi.org/10.3390/cancers13246314